Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00188695
Status:
COMPLETED
Last Update Posted:
2022-10-07
First Post:
2005-09-12
Brief Title:
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test whether or not a new contrast agent called Combidex a contrast agent formulated from ultra-small superparamagnetic iron oxide USPIO improves the ability of Magnetic Resonance Imaging MRI to see lymph nodes in the pelvis It might also help doctors tell whether or not cancer has spread to these lymph nodes It might allow radiotherapy to be delivered more accurately
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None